TABLE V.
Univariate logistic regression analysis of factors associated with postoperative inflammatory complications
| Variable | Patients [n (%)] | OR | 95% CI | p Value | ||
|---|---|---|---|---|---|---|
|
| ||||||
| All | With complicationsa | |||||
| Sex | Women | 41 | 2 (4.9) | Reference | ||
| Men | 115 | 17 (14.8) | 3.4 | 0.7 to 15.3 | 0.114 | |
|
| ||||||
| Age | <65 Years | 105 | 12 (11.4) | Reference | ||
| ≥65 Years | 51 | 7 (13.7) | 1.2 | 0.5 to 3.3 | 0.681 | |
|
| ||||||
| BMI group | 18.5–25 | 97 | 10 (10.3) | Reference | ||
| <18.5 | 10 | 0 (0.0) | — | 0.999 | ||
| ≥25 | 49 | 9 (18.4) | 2.0 | 0.7 to 5.2 | 0.177 | |
|
| ||||||
| NRS 2002 score group | <3 | 92 | 9 (9.8) | Reference | ||
| ≥3 | 64 | 10 (15.6) | 1.7 | 0.7 to 4.5 | 0.276 | |
|
| ||||||
| Diabetes | No | 146 | 18 (12.3) | Reference | ||
| Yes | 10 | 1 (10.0) | 0.8 | 0.1 to 6.6 | 0.828 | |
|
| ||||||
| Other comorbidities | No | 94 | 10 (10.6) | Reference | ||
| Yes | 62 | 9 (14.5) | 1.4 | 0.6 to 3.7 | 0.47 | |
|
| ||||||
| Neoadjuvant CTx | No | 121 | 14 (11.6) | Reference | ||
| Yes | 35 | 5 (14.3) | 1.3 | 0.4 to 3.8 | 0.666 | |
|
| ||||||
| Resection type | Subtotal | 111 | 15 (13.5) | Reference | ||
| Total | 45 | 4 (8.9) | 0.6 | 0.2 to 2.0 | 0.427 | |
|
| ||||||
| Histologic type | Well differentiated | 6 | 1 (16.7) | Reference | ||
| Moderately differentiated | 50 | 7 (14.0) | 0.8 | 0.1 to 8.0 | 0.86 | |
| Poorly differentiated | 100 | 11 (11.0) | 0.6 | 0.1 to 5.8 | 0.618 | |
|
| ||||||
| TNM stage | I | 48 | 5 (10.4) | Reference | ||
| II | 27 | 3 (11.1) | 1.1 | 0.2 to 4.9 | 0.926 | |
| III | 81 | 11 (13.6) | 1.4 | 0.4 to 4.2 | 0.599 | |
|
| ||||||
| IGF-1 | ≥75 μg/L | 128 | 16 (12.5) | Reference | ||
| <75 μg/L | 28 | 3 (10.7) | 0.8 | 0.2 to 3.1 | 0.794 | |
|
| ||||||
| Albumin | ≥35 g/L | 146 | 18 (12.3) | Reference | ||
| <35 g/L | 10 | 1 (10.0) | 0.8 | 0.1 to 6.6 | 0.828 | |
|
| ||||||
| Prealbumin | ≥150 mg/L | 135 | 15 (11.1) | Reference | ||
| <150 mg/L | 21 | 4 (19.0) | 1.9 | 0.6 to 6.3 | 0.307 | |
|
| ||||||
| Transferrin | ≥2.5 g/L | 146 | 18 (12.3) | Reference | ||
| <2.5 g/L | 10 | 1 (10.0) | 0.8 | 0.1 to 6.6 | 0.828 | |
|
| ||||||
| Retinol-binding protein | ≥25 mg/L | 110 | 12 (10.9) | Reference | ||
| <25 mg/L | 46 | 7 (15.2) | 1.5 | 0.5 to 4.0 | 0.455 | |
|
| ||||||
| Hemoglobin | ≥110 g/L | 127 | 15 (11.8) | Reference | ||
| <110 g/L | 29 | 4 (13.8) | 1.2 | 0.4 to 3.9 | 0.769 | |
|
| ||||||
| Platelets | ≥100×109/L | 135 | 15 (11.1) | Reference | ||
| <100×109/L | 21 | 4 (19.0) | 1.9 | 0.6 to 6.3 | 0.307 | |
|
| ||||||
| Lymphocytes | ≥1.0×109/L | 132 | 14 (10.6) | Reference | ||
| <1.0×109/L | 24 | 5 (20.8) | 2.2 | 0.7 to 6.9 | 0.167 | |
|
| ||||||
| Sarcopenia | No | 132 | 15 (11.4) | Reference | ||
| Yes | 24 | 4(16.7) | 1.6 | 0.5 to 5.2 | 0.468 | |
|
| ||||||
| Myosteatosis | No | 25 | 0 (0.0) | Reference | ||
| Yes | 131 | 19 (14.5) | — | 0.998 | ||
|
| ||||||
| Visceral obesity | No | 92 | 6 (6.5) | Reference | ||
| Yes | 64 | 13 (20.3) | 3.6 | 1.3 to 10.2 | 0.013 | |
a
Inflammatory complications.
OR = odds ratio; CI = confidence interval; BMI = body mass index; NRS = Nutritional Risk Screening; CTx = chemotherapy; IGF-1 = insulin-like growth factor 1.